VJOncology is committed to improving our service to you

ELCC 2019 | Afatinib for advanced EGFRm-positive NSCLC

VJOncology is committed to improving our service to you

Antonio Passaro

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, presents interim data from a phase IIIB trial, comparing the outcomes of afatinib in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients with or without prior chemotherapy treatment. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter